NEW YORK — Henry Schein said on Wednesday that it has signed on as the exclusive US distributor of a point-of-care SARS-CoV-2 test kit commercialized by Becton Dickinson and BioMedomics.
The test, developed and manufactured by BioMedomics, is designed to detect immunoglobulin M and immunoglobulin G antibodies associated with SARS-CoV-2 infection in blood, serum, or plasma. Results are available within 15 minutes.
The test was launched on Tuesday by Morrisville, North Carolina-based BioMedomics in partnership with BD, and will now be exclusively distributed to healthcare professionals in the US by Henry Schein.
"The BioMedomics serology test has been validated in numerous hospitals around the world and will be a critical tool to detect current or past exposure to COVID-19," Dave Hickey, president of Integrated Diagnostic Solutions for BD, said in a statement.
The test has not been reviewed by the US Food and Drug Administration but is being offered for use in the US under public health emergency guidance issued by the agency last month.
Last week, Melville, New York-based Henry Schein signed an agreement to distribute SD Biosensor's point-of-care immunochromatography test for SARS-CoV-2 in the US.